Stock Scorecard
Stock Summary for Jazz Pharmaceuticals plc (JAZZ) - $161.55 as of 1/12/2026 8:10:55 PM EST
Total Score
8 out of 30
Safety Score
42 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for JAZZ
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for JAZZ
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for JAZZ
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for JAZZ
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for JAZZ (42 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 0 |
| Book Value (Max of 10) | 9 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 5 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Financial Details for JAZZ
Company Overview |
|
|---|---|
| Ticker | JAZZ |
| Company Name | Jazz Pharmaceuticals plc |
| Country | N/A |
| Description | Jazz Pharmaceuticals PLC is a prominent biopharmaceutical company based in Dublin, Ireland, with a primary focus on developing and commercializing innovative therapies to address unmet medical needs in neurology, rare diseases, and hematology. The company boasts a comprehensive pipeline and a strong global presence, highlighting its commitment to enhancing patient outcomes through targeted research and development. By leveraging strategic collaborations and a deep understanding of disease mechanisms, Jazz is uniquely positioned to drive transformative change in healthcare and improve the lives of patients globally. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 161.55 |
| Price 4 Years Ago | 159.31 |
| Last Day Price Updated | 1/12/2026 8:10:55 PM EST |
| Last Day Volume | 1,222,635 |
| Average Daily Volume | 1,064,590 |
| 52-Week High | 182.99 |
| 52-Week Low | 95.49 |
| Last Price to 52 Week Low | 69.18% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 59.48 |
| Sector PE | 123.98 |
| 5-Year Average PE | -9.57 |
| Free Cash Flow Ratio | 7.94 |
| Industry Free Cash Flow Ratio | 12.53 |
| Sector Free Cash Flow Ratio | 29.04 |
| Current Ratio Most Recent Quarter | 1.65 |
| Total Cash Per Share | 20.34 |
| Book Value Per Share Most Recent Quarter | 65.18 |
| Price to Book Ratio | 2.62 |
| Industry Price to Book Ratio | 66.60 |
| Sector Price to Book Ratio | 24.69 |
| Price to Sales Ratio Twelve Trailing Months | 2.49 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.26 |
| Sector Price to Sales Ratio Twelve Trailing Months | 19.33 |
| Analyst Buy Ratings | 10 |
| Analyst Strong Buy Ratings | 4 |
Share Statistics |
|
| Total Shares Outstanding | 60,765,000 |
| Market Capitalization | 9,816,585,750 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 2.75% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 19.30% |
| Annual Earnings Growth | 35.02% |
| Reported EPS 12 Trailing Months | -6.15 |
| Reported EPS Past Year | -1.64 |
| Reported EPS Prior Year | 21.19 |
| Net Income Twelve Trailing Months | -368,484,000 |
| Net Income Past Year | 560,120,000 |
| Net Income Prior Year | 414,832,000 |
| Quarterly Revenue Growth YOY | 6.70% |
| 5-Year Revenue Growth | 13.48% |
| Operating Margin Twelve Trailing Months | 22.30% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 1,236,070,000 |
| Total Cash Past Year | 2,412,864,000 |
| Total Cash Prior Year | 1,506,310,000 |
| Net Cash Position Most Recent Quarter | -3,095,912,000 |
| Net Cash Position Past Year | -3,664,776,000 |
| Long Term Debt Past Year | 6,077,640,000 |
| Long Term Debt Prior Year | 5,107,988,000 |
| Total Debt Most Recent Quarter | 4,331,982,000 |
| Equity to Debt Ratio Past Year | 0.40 |
| Equity to Debt Ratio Most Recent Quarter | 0.48 |
| Total Stockholder Equity Past Year | 4,093,756,000 |
| Total Stockholder Equity Prior Year | 3,736,997,000 |
| Total Stockholder Equity Most Recent Quarter | 3,959,030,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 1,312,459,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 21.60 |
| Free Cash Flow Past Year | 1,347,838,000 |
| Free Cash Flow Prior Year | 1,068,045,000 |
Options |
|
| Put/Call Ratio | 0.12 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 0.31 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 125.06 |
| 200-Day SMA | 131.76 |
System |
|
| Modified | 1/10/2026 1:44:58 AM EST |